Press Releases


Latest News


Adamas Announces Positive Top-Line Phase 3 Results of ADS-5102 for the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease
Dec 23, 2015 | General Releases

Adamas to Host Conference Call and Webcast to Provide Company Update
Dec 22, 2015 | General Releases

Adamas Completes Enrollment of Its Phase 3 EASE LID 3 Study Evaluating ADS-5102 for Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
Dec 14, 2015 | General Releases

Adamas Pharmaceuticals to Present at the 27th Annual Piper Jaffray Healthcare Conference
Nov 17, 2015 | General Releases

Adamas Reports Third Quarter 2015 Financial Results
Nov 12, 2015 | Financial Releases

Adamas Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference
Oct 27, 2015 | General Releases

Adamas Presents Nonclinical Findings Supporting the Potential Use of ADS-5102 for the Treatment of Multiple Sclerosis Gait
Oct 12, 2015 | General Releases

Adamas Pharmaceuticals to Present at BioCentury's NewsMakers in the Biotech Industry Conference
Aug 27, 2015 | General Releases

Adamas Reports Second Quarter 2015 Financial Results
Aug 11, 2015 | Financial Releases

Adamas Completes Recruitment of Its Phase 3 EASE LID Study Evaluating ADS-5102 for the Treatment of Levodopa-induced Dyskinesia Associated With Parkinson's Disease
Jul 9, 2015 | General Releases

Pages:  1 2 3 4 5 6 7 8 9 10 11